Inflectra and Weight loss - a phase IV clinical study of FDA data

Summary:

Weight loss is reported as a side effect among people who take Inflectra (infliximab-dyyb), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Methotrexate, and have Crohn's disease.

The phase IV clinical study analyzes which people have Weight loss when taking Inflectra. It is created by eHealthMe based on reports of 52,342 people who have side effects when taking Inflectra from the FDA, and is updated regularly.

What is Inflectra?

Inflectra has active ingredients of infliximab-dyyb. eHealthMe is studying from 52,370 Inflectra users. Check the latest studies of Inflectra.

What is Weight loss?

Weight loss is found to be associated with 1,449 drugs and 2,293 conditions by eHealthMe. Check the latest studies of Weight loss.

On May, 26, 2026

52,342 people reported to have side effects when taking Inflectra.
Among them, 76 people (0.15%) have Weight loss.

Among these 76 people:

How long have people been on Inflectra when they have Weight loss? *

What is the gender of people who have Weight loss when taking Inflectra? *

female: 100 %
male: 0.0 %

What is the age of people who have Weight loss when taking Inflectra? *

What are other drugs people take besides Inflectra? *

What are other side effects people have besides Weight loss? *

Weight Increased: 40 people, 52.63%
Pain: 30 people, 39.47%
Fatigue (feeling of tiredness): 28 people, 36.84%
Drug Ineffective: 26 people, 34.21%
Joint Pain: 25 people, 32.89%
Weight Decreased: 24 people, 31.58%
Blood Pressure Fluctuation: 22 people, 28.95%
High Blood Pressure: 20 people, 26.32%
Nasopharyngitis (inflammation of the nasopharynx): 20 people, 26.32%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 19 people, 25.00%

What are the existing conditions these people have? *

Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 29 people, 38.16%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 18 people, 23.68%
Ankylosing Spondylitis (type of arthritis affecting the spine): 13 people, 17.11%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 8 people, 10.53%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 7 people, 9.21%
Urinary Tract Infection: 6 people, 7.89%
Pain: 6 people, 7.89%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 5 people, 6.58%
Sleep Disorder: 5 people, 6.58%
Psoriasis (immune-mediated disease that affects the skin): 5 people, 6.58%

* Approximation only. Some reports may have incomplete information.

Do you take Inflectra and have Weight loss?

- Check whether Weight loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Inflectra:

Inflectra (52,370 reports)

Weight loss treatments and more:

Weight loss (62,430 reports)

Browse all side effects of Inflectra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weight loss:

Weight loss (1,449 drugs)

Browse all the conditions that are associated with Weight loss:

Weight loss (2,293 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on infliximab-dyyb (the active ingredients of Inflectra) and Inflectra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.